Catalent Secures Manufacturing Contract for Pfizer’s OTC Heartburn Treatment
PTSM: Pharmaceutical Technology Sourcing and Management
Catalent has entered into an exclusive long-term supply agreement to produce Pfizer’s OTC proton-pump inhibitor for heartburn treatment, Nexium 24HR (esomeprazole), which is also marketed as Nexium Control outside the US.
Catalent Pharma Solutions has entered into an exclusive long-term supply agreement to produce Pfizer’s over-the-counter (OTC) proton-pump inhibitor for heartburn treatment, Nexium 24HR (esomeprazole), which is also marketed as Nexium Control outside the United States. Production will be carried out at the CDMO’s Winchester, Kentucky facility. The drug will be formulated and manufactured into enteric-coated, delayed-release pellets using fluid-bed technology. Catalent will also encapsulate these pellets into two-piece, hard-shell capsules using its capsule banding technology for OTC products.
Pfizer secured exclusive global rights to market Nexium for OTC indications from AstraZeneca in 2012. AstraZeneca continues to manufacture and sell the prescription product.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
